<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fragile X syndrome: Clinical features and diagnosis in children and adolescents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fragile X syndrome: Clinical features and diagnosis in children and adolescents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Fragile X syndrome: Clinical features and diagnosis in children and adolescents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hilde Van Esch, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helen V Firth, DM, FRCP, FMedSci</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert G Voigt, MD, FAAP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 13, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Fragile X syndrome (FXS) is an X-linked disorder and the most common inherited cause of intellectual disability [<a href="#rid1">1</a>]. Both males and females can be affected.</p><p>The clinical features and diagnosis of FXS in children and adolescents are discussed in this topic review. Prenatal screening and the management of FXS in children and adolescents are discussed separately. (See  <a class="medical medical_review" href="/d/html/437.html" rel="external">"Fragile X syndrome: Prenatal screening and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2925.html" rel="external">"Fragile X syndrome: Management in children and adolescents"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>FXS is an X-linked disorder. It is caused by a loss-of-function variant in the fragile X messenger ribonucleoprotein 1 (<em>FMR1</em>) gene located at Xq27.3 that results in decreased or absent levels of fragile X messenger ribonucleoprotein (FMRP) [<a href="#rid2">2,3</a>]. In more than 99 percent of cases, loss of function is caused by an unstable expansion of a trinucleotide (cytosine-guanine-guanine [CGG]) repeat at the 5' untranslated region of the gene [<a href="#rid4">4,5</a>]. Deletions, point mutations, and missense mutations in <em>FMR1</em> also may cause FXS but are very rare [<a href="#rid4">4,6,7</a>].</p><p>There are two clinically significant levels of CGG expansion:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Full mutation </strong>– Expansion of &gt;200 repeats is known as full mutation and leads to methylation-coupled silencing of the <em>FMR1</em> gene and absence of FMRP, causing the classical FXS phenotype. (See <a class="local">'Full mutation in males'</a> below and <a class="local">'Full mutation in females'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Premutation </strong>– A smaller expansion of between approximately 50 to 55 and 200 repeats is known as premutation. The <em>FMR1</em> gene remains transcriptionally active, FMRP is produced, and the classic FXS phenotype does not occur. However, a spectrum of clinical findings is associated with the premutation. Premutation alleles exhibit instability upon transmission, especially from a carrier mother, and may result in a full mutation in one or more generations [<a href="#rid8">8-11</a>]. (See <a class="local">'Premutation'</a> below.)</p><p></p><p>DNA methylation turns off gene activity, thus preventing gene transcription. Elongation of the CGG repeats allows hypermethylation of <em>FMR1</em>, resulting in impaired transcription and reduced production of the FMRP. Lower levels of FMRP appear to have a major impact upon the severity of the FXS phenotype. Individuals with nearly normal levels of FMRP may have mild or no symptoms, while those with very little or no normal FMRP may have more severe symptoms. (See  <a class="medical medical_review" href="/d/html/14601.html" rel="external">"Principles of epigenetics", section on 'DNA methylation'</a>.)</p><p>The genetics and molecular biology of FXS are discussed in detail separately [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/437.html" rel="external">"Fragile X syndrome: Prenatal screening and diagnosis", section on 'Pathophysiology'</a>.)</p><p class="headingAnchor" id="H3365848815"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>FXS (MIM #300624) is the most frequent form of inherited intellectual disability, with a disease prevalence due to the full mutation of between 1 in 4000 and 1 in 7000 in males [<a href="#rid1">1,4,13</a>]. The prevalence of the full mutation in females, which has a variable clinical presentation, is approximately two-thirds to one-half of that in males [<a href="#rid4">4,13</a>]. However, this prevalence measure may be inappropriately low as females with a mild phenotype may go undiagnosed. The premutation rate is approximately 1 in 750 to 1 in 850 men and 1 in 250 to 1 in 300 in women [<a href="#rid1">1,13-15</a>]. FXS has been diagnosed in up to 3 percent of males with significant neurodevelopmental disorders (eg, autism, nonsyndromic intellectual disability) [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>The clinical features of FXS vary depending upon the mutation state (full mutation versus premutation), degree of methylation, sex, tissue variation/mosaicism, and possibly magnitude of the fragile X messenger ribonucleoprotein (FMRP) deficit  (<a class="graphic graphic_table graphicRef73067" href="/d/graphic/73067.html" rel="external">table 1</a>) [<a href="#rid4">4,5,16-19</a>]. Males with the full mutation are usually significantly affected. The degree of impairment varies widely in females with the full mutation.</p><p class="headingAnchor" id="H7"><span class="h2">Full mutation in males</span><span class="headingEndMark"> — </span>All males with the full mutation have manifestations of FXS, but there is a wide range of physical, cognitive, and behavioral features [<a href="#rid20">20</a>]. The physical features may be subtle. The classic presentation is a young male with global developmental delay and typical behavioral characteristics, described below. Males with FXS are at variable risk for autism spectrum disorders (ASD) and attention deficit hyperactivity disorder (ADHD) [<a href="#rid21">21,22</a>]. (See <a class="local">'Cognitive function'</a> below and <a class="local">'Behavioral features'</a> below and <a class="local">'Autism'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h3">Physical features</span><span class="headingEndMark"> — </span>The physical features of FXS in males vary depending upon age [<a href="#rid16">16,23-27</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adolescents </strong>- The classic physical manifestations are more obvious in adolescents  (<a class="graphic graphic_picture graphicRef104833" href="/d/graphic/104833.html" rel="external">picture 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Long and narrow face with prominent forehead and chin (prognathism)</p><p class="bulletIndent2"><span class="glyph">•</span>Large ears</p><p class="bulletIndent2"><span class="glyph">•</span>Testicular enlargement (volume &gt;25 mL after puberty) with normal testicular function</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infants and children </strong>– Physical manifestations are subtle in infants and children. Nonetheless, some craniofacial and connective tissue findings may be present from a young age  (<a class="graphic graphic_picture graphicRef60035" href="/d/graphic/60035.html" rel="external">picture 2</a>). These include [<a href="#rid16">16,20,25,28-30</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Relative macrocephaly (head circumference &gt;50<sup>th</sup> percentile for age and sex) [<a href="#rid4">4</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Strabismus</p><p class="bulletIndent2"><span class="glyph">•</span>Pale blue irises</p><p class="bulletIndent2"><span class="glyph">•</span>Midface hypoplasia with sunken eyes</p><p class="bulletIndent2"><span class="glyph">•</span>Arched palate</p><p class="bulletIndent2"><span class="glyph">•</span>Mitral valve prolapse (seemingly benign)</p><p class="bulletIndent2"><span class="glyph">•</span>Joint hyperlaxity (particularly of the thumbs, fingers, and wrists)</p><p class="bulletIndent2"><span class="glyph">•</span>Hypotonia</p><p class="bulletIndent2"><span class="glyph">•</span>Doughy skin over the dorsum of hands</p><p class="bulletIndent2"><span class="glyph">•</span>Flexible flat feet</p><p></p><p>Testicular enlargement is usually not seen in males under eight years of age [<a href="#rid24">24,31</a>].</p><p>Macrocephaly is related to underlying structural anomalies. Magnetic resonance imaging and quantitative morphometry demonstrate that individuals with an <em>FMR1</em> gene full mutation have increased total brain volume, with relatively increased caudate nucleus, fourth ventricle, and hippocampal volumes and decreased cerebellar vermis volume [<a href="#rid32">32-34</a>]. In addition, males with FXS have decreased lateral ventricle volume [<a href="#rid32">32</a>]. Caudate nucleus volume correlates with the methylation status of the <em>FMR1</em> gene, and both caudate nucleus and lateral ventricular volumes correlate with intelligence quotient (IQ).</p><p class="headingAnchor" id="H9"><span class="h3">Cognitive function</span><span class="headingEndMark"> — </span>Developmental delay (including delayed attainment of motor and language milestones), intellectual disability, and learning disabilities are the most salient clinical features of FXS [<a href="#rid35">35</a>]. In addition, cognitive level and adaptive behavior skills decline after early childhood, reflecting the slow acquisition of skills compared with other children of the same age rather than a regression of skills [<a href="#rid20">20,36-40</a>]. The decline occurs in all areas: quantitative skills, verbal reasoning, visual/abstract abilities, and short-term memory [<a href="#rid38">38</a>]. These observations highlight the importance of early intervention to facilitate cognitive abilities and adaptive behavior skills [<a href="#rid20">20,39</a>]. FXS is unlikely in the child with normal intelligence. (See <a class="local">'Diagnosis'</a> below and  <a class="medical medical_review" href="/d/html/2925.html" rel="external">"Fragile X syndrome: Management in children and adolescents"</a>.)</p><p>Males with FXS typically sit alone at 10 months, walk at 20.6 months, and say their first clear words at 20 months (compared with approximately 7 months, 13 months, and 11 months, respectively, in typically developing children) [<a href="#rid4">4</a>].</p><p>Males with FXS have delayed language development. Expressive language skills are achieved more slowly than receptive language skills, and the discrepancy between expressive and receptive skills increases with age [<a href="#rid35">35,41</a>]. Approximately 10 percent of males with FXS are nonverbal [<a href="#rid42">42</a>].</p><p>Expressive language is often tangential (eg, responses or comments that do not relate to the topic of conversation) and perseverative, with inappropriate self-repetition, echolalia (involuntary parrot-like repetition), and pragmatic errors [<a href="#rid20">20,35,43</a>].</p><p>Articulation is poor, and language is repetitive and characterized by short and fast utterances [<a href="#rid44">44</a>]. Cluttering is often present. Cluttering is a rapid, fluctuating rate of speech with repetitions of sounds, words, and phrases and occasional garbled, slurred, or disorganized speech.</p><p>Prepubertal males with FXS, particularly preschoolers, generally have higher IQs than adolescents and adults with FXS [<a href="#rid44">44</a>]. Adult males typically have an IQ in the moderate intellectual disability range, but intellectual disability ranges from mild to severe. (See  <a class="medical medical_review" href="/d/html/6172.html" rel="external">"Intellectual disability (ID) in children: Clinical features, evaluation, and diagnosis", section on 'Severity classification'</a>.)</p><p>Although individual strengths and weaknesses may vary from patient to patient, common strengths among males with FXS include verbal skills (verbal reasoning, simple labeling, vocabulary, verbal comprehension) [<a href="#rid20">20</a>]. Common weaknesses include mathematics abilities, visuospatial abilities, attention and executive function (eg, the ability to organize information, plan ahead, problem solve), and visual-motor coordination [<a href="#rid20">20,36,45-47</a>].</p><p class="headingAnchor" id="H11"><span class="h3">Behavioral features</span><span class="headingEndMark"> — </span>Males with FXS often have neurobehavioral disabilities, including ADHD, anxiety, and ASD [<a href="#rid22">22,36,48-51</a>]. Clinical features include hyperactivity, inattention, gaze aversion, and stereotypic movements, such as hand flapping, hyperarousal, social anxiety, unusual speech patterns. (See  <a class="medical medical_review" href="/d/html/627.html" rel="external">"Autism spectrum disorder in children and adolescents: Clinical features", section on 'Restricted and repetitive behavior, interests, and activities'</a> and <a class="local">'Autism'</a> below and  <a class="medical medical_review" href="/d/html/624.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Core symptoms'</a> and  <a class="medical medical_review" href="/d/html/624.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Clinical features'</a>.)</p><p>Males with FXS tend to be more inattentive, overactive, and impulsive than males with other types of intellectual disability [<a href="#rid48">48</a>]. These symptoms may be related to sensory hyperreactivity and lack of stimulus inhibition and may lead to a diagnosis of ADHD. These symptoms tend to decline with age, but many adult males with FXS remain hyperactive. Treatment with stimulant medication may be beneficial [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/2925.html" rel="external">"Fragile X syndrome: Management in children and adolescents", section on 'Hyperactivity and inattention'</a>.)</p><p>Males with FXS may have avoidant behaviors, particularly when their intellectual disability is severe [<a href="#rid49">49</a>]. They tend to avoid new situations and to move away from new objects [<a href="#rid48">48</a>]. However, they do not remain socially withdrawn, unless they have ASD, or avoid familiar people.</p><p>Males with FXS also may have anxiety symptoms (nervousness, obsessive-compulsive disorder-like obsessions), mood instability, aggressive behavior, and self-injurious behavior [<a href="#rid52">52-54</a>].</p><p class="headingAnchor" id="H2224858294"><span class="h3">Autism</span><span class="headingEndMark"> — </span>It is estimated that 18 to 67 percent of males with FXS meet the criteria for ASD [<a href="#rid49">49,55,56</a>]. Males with FXS and autism have greater impairments in cognitive skills, social interaction, academic achievement, language ability, and adaptive behavior than males with FXS alone and are also more likely to have seizures [<a href="#rid5">5,57-60</a>]. (See  <a class="medical medical_review" href="/d/html/628.html" rel="external">"Autism spectrum disorder in children and adolescents: Evaluation and diagnosis", section on 'Evaluation for associated conditions'</a> and  <a class="medical medical_review" href="/d/html/627.html" rel="external">"Autism spectrum disorder in children and adolescents: Clinical features"</a>.)</p><p class="headingAnchor" id="H1595289582"><span class="h3">Seizures</span><span class="headingEndMark"> — </span>Approximately 10 to 20 percent of males with FXS develop seizures [<a href="#rid61">61-63</a>]. The risk of seizures is highest in childhood (peak incidence between six months and four years; mean age of onset two years) [<a href="#rid5">5,62,63</a>]. Most are simple or complex partial seizures, including benign childhood epilepsy with centrotemporal spikes (also known as benign rolandic epilepsy), although other types can occur. The seizures are relatively easy to control and often spontaneously remit during childhood [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/6158.html" rel="external">"Self-limited focal epilepsies of childhood", section on 'Self-limited epilepsy with centrotemporal spikes (SeLECTS)'</a> and  <a class="medical medical_review" href="/d/html/2925.html" rel="external">"Fragile X syndrome: Management in children and adolescents", section on 'Seizures'</a>.)</p><p class="headingAnchor" id="H1561050720"><span class="h3">Additional associated findings</span><span class="headingEndMark"> — </span>Children with FXS can have slow motor development and often present with hypotonia in infancy. Infants with hypotonia can have associated feeding problems, gastroesophageal reflux, and recurrent otitis. (See  <a class="medical medical_review" href="/d/html/2925.html" rel="external">"Fragile X syndrome: Management in children and adolescents", section on 'Evaluation to determine extent of disease'</a>.)</p><p>Strabismus, joint laxity, and mitral valve prolapse may also be present. Except for strabismus, these findings usually do not demand surgical intervention.</p><p class="headingAnchor" id="H12"><span class="h3">Prader-Willi phenotype</span><span class="headingEndMark"> — </span>A subgroup of males with FXS has a phenotype similar to that of Prader-Willi syndrome (PWS; ie, obesity and hyperphagia) but do not have the characteristic cytogenetic or methylation abnormalities at 15q11-13 [<a href="#rid64">64-67</a>]. Autism is more common in males with FXS and the Prader-Willi phenotype than in males with FXS without the Prader-Willi phenotype (54 versus approximately 30 percent) [<a href="#rid67">67</a>]. (See  <a class="medical medical_review" href="/d/html/5864.html" rel="external">"Prader-Willi syndrome: Management"</a> and  <a class="medical medical_review" href="/d/html/5875.html" rel="external">"Prader-Willi syndrome: Clinical features and diagnosis"</a> and <a class="local">'Autism'</a> above.)</p><p class="headingAnchor" id="H13"><span class="h2">Full mutation in females</span><span class="headingEndMark"> — </span>The phenotype of full-mutation FXS in females is much more variable than in males because of individual differences in inactivation of the fragile X chromosome [<a href="#rid20">20</a>]. Approximately 50 percent of females with a full fragile X mutation have normal intellect. The remaining 50 percent usually have milder features than males, but the full spectrum of cognitive, behavioral, and physical findings may occur [<a href="#rid16">16</a>].</p><p>As many as 50 percent of females with the full mutation have some of the characteristic physical features (eg, prominent ears) [<a href="#rid68">68</a>]. Approximately 50 percent of women with the full mutation have Iqs in the borderline or mild intellectual disability range [<a href="#rid68">68-71</a>]. Cognitive impairment appears to correlate with the activation ratio of the fragile X chromosome rather than the size of the amplification [<a href="#rid72">72</a>]. As in males with full-mutation FXS, cognitive function may decline after early childhood. (See  <a class="medical medical_review" href="/d/html/6172.html" rel="external">"Intellectual disability (ID) in children: Clinical features, evaluation, and diagnosis"</a>.)</p><p>Many females with the full mutation have associated behavioral or emotional problems [<a href="#rid52">52,68,73</a>]. They typically present with learning difficulties (especially in math), attention problems (or ADHD), shyness, social anxiety, or selective mutism [<a href="#rid42">42</a>]. Deficits in visual-motor coordination, executive function (eg, the ability to organize information, plan ahead, problem solve), and language are common [<a href="#rid42">42,74-76</a>]. Females with the full mutation are at risk for affective and schizophrenia spectrum disorders [<a href="#rid52">52,77</a>]. Autistic behaviors (eg, communication and social interaction deficits, stereotypies) are more commonly reported among 6- to 16-year-old females with FXS than age- and IQ-matched controls [<a href="#rid78">78</a>]. Approximately 20 percent of females with FXS meet the criteria for ASD [<a href="#rid49">49,55,56</a>]. (See  <a class="medical medical_review" href="/d/html/610.html" rel="external">"Specific learning disorders in children: Clinical features", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/d/html/624.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Core symptoms'</a> and  <a class="medical medical_review" href="/d/html/624.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/d/html/627.html" rel="external">"Autism spectrum disorder in children and adolescents: Clinical features"</a>.)</p><p>Approximately 5 percent of females with FXS develop seizures [<a href="#rid61">61-63</a>]. (See <a class="local">'Seizures'</a> above.)</p><p class="headingAnchor" id="H14"><span class="h2">Premutation</span><span class="headingEndMark"> — </span>Individuals with fragile X premutation have between 55<em> </em>and 200 cytosine-guanine-guanine (CGG) repeats. At this level, the <em>FMR1</em> gene remains transcriptionally active, and the classic FXS phenotype does not occur. (See <a class="local">'Pathogenesis'</a> above.)</p><p>There are three potential areas of concern for individuals with fragile X premutations:</p><p class="bulletIndent1"><span class="glyph">●</span>Premature ovarian insufficiency (POI) in women, which is discussed separately (see  <a class="medical medical_review" href="/d/html/7443.html" rel="external">"Clinical manifestations and diagnosis of primary ovarian insufficiency (premature ovarian failure)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fragile X-associated tremor-ataxia syndrome (FXTAS) later in life, which is discussed separately (see  <a class="medical medical_review" href="/d/html/6230.html" rel="external">"Autosomal dominant spinocerebellar ataxias", section on 'Fragile X-associated tremor/ataxia syndrome'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurocognitive deficits [<a href="#rid79">79</a>]</p><p></p><p>In the past, fragile X premutation was not thought to affect cognitive function. However, there are reports of individuals with premutation and neurobehavioral manifestations, including cognitive and social skills deficits, anxiety, executive dysfunction, and autism [<a href="#rid5">5,80-83</a>]. Decreased FMRP levels have been detected in some of these individuals, suggesting a spectrum of clinical severity related to relative FMRP deficit [<a href="#rid80">80,84</a>].</p><p>The author's clinical practice has identified several males with fragile X premutation and learning problems, developmental delay, or autistic features. This may reflect an ascertainment bias. However, they have identified four times more premutations in males younger than 16 years with developmental problems who were referred for <em>FMR1</em> gene testing than would be expected based upon the known prevalence of the premutation in males (unpublished data). Larger and more longitudinal studies are necessary, but these data provide additional evidence that fragile X premutations may affect neurocognitive and behavioral functioning in children.</p><p class="headingAnchor" id="H18"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>It is important to make the diagnosis of FXS as early as possible so that appropriate interventions (eg, speech and language therapy, special education support, genetic counseling) can be initiated [<a href="#rid42">42</a>]. Surveys of parents of children diagnosed with FXS indicate a significant delay between the onset of their concerns (average age approximately 12 months) and the diagnosis of FXS (average age 35 to 37 months). Approximately one-fourth of families had a second child with a full mutation before the first child was diagnosed [<a href="#rid85">85,86</a>]. The diagnosis is based upon the phenotypic presentation as well as the genotype.</p><p class="headingAnchor" id="H19"><span class="h2">Indications for testing</span><span class="headingEndMark"> — </span>In the absence of a family history of FXS, the diagnosis of FXS requires clinical suspicion based upon cognitive, developmental, or behavioral concerns, as described above. The diagnosis is confirmed by molecular testing. (See <a class="local">'Clinical features'</a> above and <a class="local">'FMR1 DNA analysis'</a> below.)</p><p class="headingAnchor" id="H1136072153"><span class="h3">Child with suspected FXS</span><span class="headingEndMark"> — </span>The American Academy of Pediatrics Committee on Genetics recommends genetic testing for FXS (see <a class="local">'FMR1 DNA analysis'</a> below) in children with any of the following, particularly when associated with physical and behavioral characteristics of FXS or a relative with undiagnosed intellectual disability [<a href="#rid87">87</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Developmental delay</p><p class="bulletIndent1"><span class="glyph">●</span>Borderline intellectual abilities or intellectual disability</p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis of autism without a specific etiology</p><p></p><p>Although the yield of molecular testing in such individuals is low [<a href="#rid88">88</a>], early diagnosis is important for timely genetic counseling. (See  <a class="medical medical_review" href="/d/html/437.html" rel="external">"Fragile X syndrome: Prenatal screening and diagnosis", section on 'Screening'</a> and  <a class="medical medical_review" href="/d/html/628.html" rel="external">"Autism spectrum disorder in children and adolescents: Evaluation and diagnosis", section on 'Genetic testing'</a> and  <a class="medical medical_review" href="/d/html/6189.html" rel="external">"Intellectual disability in children: Evaluation for a cause", section on 'Testing for fragile X syndrome'</a>.)</p><p class="headingAnchor" id="H3619540295"><span class="h3">Adult with suspected FXS</span><span class="headingEndMark"> — </span>Genetic testing should also be offered to the following patients, after an appropriate explanation of the test and its potential implications for the patient and their family [<a href="#rid87">87</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Females with primary ovarian insufficiency (POI)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients over 50 years of age with progressive cerebellar ataxia and intention tremor</p><p class="bulletIndent1"><span class="glyph">●</span>Adults with typical physical features and intellectual disability without a specific etiology</p><p></p><p>Testing for mutations in the <em>FMR1</em> gene is also suggested for persons who had cytogenetic testing in the past if the results of the testing and the clinical/behavioral phenotype are inconsistent [<a href="#rid89">89</a>].</p><p class="headingAnchor" id="H20"><span class="h3">FXS suspected due to family history</span><span class="headingEndMark"> — </span>Family history findings that are suggestive of FXS include [<a href="#rid16">16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive effects – Intellectual disability, developmental delay, learning disabilities, specific problems with mathematics</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Speech delay or unusual speech pattern</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autism spectrum disorder (ASD) or autistic-like behaviors</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Attention deficit or attention deficit hyperactivity disorder (ADD/ADHD)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dysmorphic features – Macrocephaly, large ears, long face, broad forehead, prominent jaw, strabismus, large testicles</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Features of loose connective tissue – Hyperextensible joints, flat feet, hypotonia, mitral valve prolapse, hernias</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic symptoms – Seizures, late-onset progressive tremor, ataxia, difficulty walking, balance problems, short-term memory loss, loss of sensation in limbs</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mental illness/personality disorders – Depression, schizophrenia, bipolar disorder, obsessive-compulsive disorder, schizoaffective disorder, schizoid personality</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Behavioral problems – Impulsiveness, anger outbursts, violent behavior, solitary behavior, counseling or medication for behavioral difficulties</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Shyness, social anxiety, excessive worrying, counseling or medication for emotional difficulties</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Premature menopause, fertility problems</p><p></p><p>Molecular testing is warranted if several of these family history features are present in combination in a symptomatic person (eg, a child with developmental delay and/or behavioral problems, a woman with premature menopause, or an older male with ataxia) or in someone with a strong family history. Genetic counseling and genetic testing are also suggested for at-risk family members of patients with FXS, even if they are asymptomatic.</p><p class="headingAnchor" id="H21"><span class="h2">FMR1 DNA analysis</span><span class="headingEndMark"> — </span>The diagnosis of FXS is based upon detection of an alteration in the <em>FMR1</em> gene [<a href="#rid4">4</a>]. Measuring the number of repeats in the CGG segment of <em>FMR1 </em>is used to identify persons with premutation or full mutation, in addition to those who have a normal or intermediate number of repeats. Testing methods and indications for prenatal screening are discussed separately. In addition, a detailed description of molecular genetic tests and the testing strategy for<em> FMR1</em>-related disorders is available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=2924" target="_blank">Genetic Testing Registry (GTR).</a> (See  <a class="medical medical_review" href="/d/html/437.html" rel="external">"Fragile X syndrome: Prenatal screening and diagnosis", section on 'Preconception and prenatal screening'</a> and  <a class="medical medical_review" href="/d/html/437.html" rel="external">"Fragile X syndrome: Prenatal screening and diagnosis", section on 'Laboratory testing'</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of FXS includes other causes of intellectual disability or developmental delay, including [<a href="#rid4">4,90,91</a>] (see  <a class="medical medical_review" href="/d/html/6172.html" rel="external">"Intellectual disability (ID) in children: Clinical features, evaluation, and diagnosis"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fragile XE syndrome (FRAXE)</strong> – FRAXE, which is extremely rare, is characterized by mild intellectual disability without consistent physical features. It has been described in males with expanded cytosine-cytosine-guanine (CCG) repeats in AF4/FMR2 family member 2 (<em>AFF2</em>) gene, near the <em>FMR1</em> gene.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>XXY (Klinefelter syndrome)</strong> – Males with Klinefelter syndrome may have specific learning disabilities, particularly in expressive language. In contrast to postpubertal males with FXS, males with XXY usually have small testes. (See  <a class="medical medical_review" href="/d/html/5848.html" rel="external">"The child with tall stature and/or abnormally rapid growth", section on 'Klinefelter syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cerebral gigantism (Sotos syndrome)</strong> – Characteristic features of cerebral gigantism include typical facial appearance (macrocephaly, frontal bossing, prominent chin, pointed chin, downslanting palpebral fissures), overgrowth, learning disability, behavioral problems, and congenital cardiac anomalies. (See  <a class="medical medical_review" href="/d/html/5848.html" rel="external">"The child with tall stature and/or abnormally rapid growth", section on 'Cerebral gigantism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prader-Willi syndrome (PWS)</strong> – Some males with FXS have a phenotype similar to that of PWS, but they do not have the genetic abnormalities associated with PWS. (See  <a class="medical medical_review" href="/d/html/5864.html" rel="external">"Prader-Willi syndrome: Management"</a> and <a class="local">'Prader-Willi phenotype'</a> above.)</p><p></p><p class="headingAnchor" id="H24"><span class="h1">RESOURCES</span><span class="headingEndMark"> — </span>FXS resources for health care providers, parents/caregivers, and patients include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffragilex.org%2F&amp;token=T5M9GKYlNl%2BZvkR9N5GxcphyL9KBPQKWKx8XOK6A184%3D&amp;TOPIC_ID=2924" target="_blank">The National Fragile X Foundation</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fraxa.org%2F&amp;token=DzPMsBhauzgvZzN%2FvOiltVNFM82Ee2OPlnJpQ%2B0J%2F0c%3D&amp;TOPIC_ID=2924" target="_blank">FRAXA Research Foundation</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nichd.nih.gov%2Fhealth%2Ftopics%2Ffragilex&amp;token=lblfowwGB6QwC91WNuiIfyvNJsdpJlnlWJNrnQcYrRXNy87fMxer7pSvGZ0X8hHdkwMP7mNF0b5AbpdCXLNR%2FQ%3D%3D&amp;TOPIC_ID=2924" target="_blank">The National Institute of Child Health and Human Development</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=2924" target="_blank">Genetic Testing Registry (GTR)</a></p><p></p><p class="headingAnchor" id="H1183095678"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118568.html" rel="external">"Society guideline links: Fragile X syndrome"</a>.)</p><p class="headingAnchor" id="H463957987"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/87575.html" rel="external">"Patient education: Fragile X syndrome (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Fragile X syndrome (FXS) is the most frequent form of inherited intellectual disability, with a prevalence between 1 in 4000 and 1 in 7000 in males. The prevalence in females is approximately two-thirds to one-half of that in males. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics/pathogenesis</strong> – FXS is an X-linked disorder. It is caused by a loss-of-function mutation in the fragile X messenger ribonucleoprotein 1 (<em>FMR1</em>) gene that leads to decreased or absent fragile X messenger ribonucleoprotein (FMRP). (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The clinical features of FXS vary depending upon the mutation state (full mutation versus premutation), degree of methylation, sex, and tissue variation  (<a class="graphic graphic_table graphicRef73067" href="/d/graphic/73067.html" rel="external">table 1</a>). (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Males with full mutation</strong> – All males with full-mutation FXS have manifestations of FXS, but there are a wide range of physical, cognitive, and behavioral features. (See <a class="local">'Full mutation in males'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Classic physical features include long and narrow face with prominent forehead and chin, large ears, and testicular enlargement, but these features typically are not obvious until adolescence or adulthood  (<a class="graphic graphic_picture graphicRef104833" href="/d/graphic/104833.html" rel="external">picture 1</a>). Physical features in younger males may include macrocephaly, strabismus, midface hypoplasia, arched palate, mitral valve prolapse, hyperextensible joints, hypotonia, soft skin, and flexible, flat feet.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Intellectual disability is usually in the moderate range. Expressive language is more affected than receptive language.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Behavioral features may include features of attention deficit hyperactivity disorder (ADHD; hyperactivity, inattention), autism spectrum disorder (ASD; gaze aversion, stereotypic movements [eg, hand flapping, hand biting], hyperarousal, social impairment, and unusual speech), or anxiety.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Females with full mutation</strong> – Females with the full mutation usually have milder features than males, and 50 percent have normal cognitive function. However, the full spectrum of cognitive, behavioral, and physical findings may occur. (See <a class="local">'Full mutation in females'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – In the absence of a family history of FXS, diagnosis of FXS requires a low threshold for clinical suspicion based upon cognitive, developmental, or behavioral concerns, as described above. Diagnosis is confirmed by molecular testing. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of FXS includes other causes of intellectual disability or developmental delay. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H3234727158"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Carolyn Bridgemohan, MD (deceased), who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Turner G, Webb T, Wake S, Robinson H. Prevalence of fragile X syndrome. Am J Med Genet 1996; 64:196.</a></li><li><a class="nounderline abstract_t">Verkerk AJ, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991; 65:905.</a></li><li><a class="nounderline abstract_t">Rooms L, Kooy RF. Advances in understanding fragile X syndrome and related disorders. Curr Opin Pediatr 2011; 23:601.</a></li><li class="breakAll">Saul RA, Tarleton JC. FMR1-related disorders. GeneReviews. www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=fragilex (Accessed on December 31, 2009).</li><li><a class="nounderline abstract_t">Hagerman RJ, Berry-Kravis E, Kaufmann WE, et al. Advances in the treatment of fragile X syndrome. Pediatrics 2009; 123:378.</a></li><li><a class="nounderline abstract_t">De Boulle K, Verkerk AJ, Reyniers E, et al. A point mutation in the FMR-1 gene associated with fragile X mental retardation. Nat Genet 1993; 3:31.</a></li><li><a class="nounderline abstract_t">Coffee B, Ikeda M, Budimirovic DB, et al. Mosaic FMR1 deletion causes fragile X syndrome and can lead to molecular misdiagnosis: a case report and review of the literature. Am J Med Genet A 2008; 146A:1358.</a></li><li><a class="nounderline abstract_t">Nolin SL, Brown WT, Glicksman A, et al. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet 2003; 72:454.</a></li><li><a class="nounderline abstract_t">Nolin SL, Glicksman A, Ersalesi N, et al. Fragile X full mutation expansions are inhibited by one or more AGG interruptions in premutation carriers. Genet Med 2015; 17:358.</a></li><li><a class="nounderline abstract_t">Latham GJ, Coppinger J, Hadd AG, Nolin SL. The role of AGG interruptions in fragile X repeat expansions: a twenty-year perspective. Front Genet 2014; 5:244.</a></li><li><a class="nounderline abstract_t">Nolin SL, Ding XH, Houck GE, et al. Fragile X full mutation alleles composed of few alleles: implications for CGG repeat expansion. Am J Med Genet A 2008; 146A:60.</a></li><li><a class="nounderline abstract_t">Hagerman RJ, Berry-Kravis E, Hazlett HC, et al. Fragile X syndrome. Nat Rev Dis Primers 2017; 3:17065.</a></li><li><a class="nounderline abstract_t">Hunter J, Rivero-Arias O, Angelov A, et al. Epidemiology of fragile X syndrome: a systematic review and meta-analysis. Am J Med Genet A 2014; 164A:1648.</a></li><li><a class="nounderline abstract_t">de Vries BB, van den Ouweland AM, Mohkamsing S, et al. Screening and diagnosis for the fragile X syndrome among the mentally retarded: an epidemiological and psychological survey. Collaborative Fragile X Study Group. Am J Hum Genet 1997; 61:660.</a></li><li><a class="nounderline abstract_t">Rousseau F, Rouillard P, Morel ML, et al. Prevalence of carriers of premutation-size alleles of the FMRI gene--and implications for the population genetics of the fragile X syndrome. Am J Hum Genet 1995; 57:1006.</a></li><li><a class="nounderline abstract_t">McConkie-Rosell A, Finucane B, Cronister A, et al. Genetic counseling for fragile x syndrome: updated recommendations of the national society of genetic counselors. J Genet Couns 2005; 14:249.</a></li><li><a class="nounderline abstract_t">McConkie-Rosell A, Lachiewicz AM, Spiridigliozzi GA, et al. Evidence that methylation of the FMR-I locus is responsible for variable phenotypic expression of the fragile X syndrome. Am J Hum Genet 1993; 53:800.</a></li><li><a class="nounderline abstract_t">Merenstein SA, Sobesky WE, Taylor AK, et al. Molecular-clinical correlations in males with an expanded FMR1 mutation. Am J Med Genet 1996; 64:388.</a></li><li><a class="nounderline abstract_t">Wright-Talamante C, Cheema A, Riddle JE, et al. A controlled study of longitudinal IQ changes in females and males with fragile X syndrome. Am J Med Genet 1996; 64:350.</a></li><li><a class="nounderline abstract_t">Visootsak J, Warren ST, Anido A, Graham JM Jr. Fragile X syndrome: an update and review for the primary pediatrician. Clin Pediatr (Phila) 2005; 44:371.</a></li><li><a class="nounderline abstract_t">Doherty BR, Longhi E, Cole V, et al. Disentangling autism spectrum and attention-deficit/hyperactivity symptoms over development in fragile X syndrome. Res Dev Disabil 2020; 104:103692.</a></li><li><a class="nounderline abstract_t">Sullivan K, Hatton D, Hammer J, et al. ADHD symptoms in children with FXS. Am J Med Genet A 2006; 140:2275.</a></li><li><a class="nounderline abstract_t">Fryns JP. The fragile X syndrome. A study of 83 families. Clin Genet 1984; 26:497.</a></li><li><a class="nounderline abstract_t">Lachiewicz AM, Dawson DV, Spiridigliozzi GA. Physical characteristics of young boys with fragile X syndrome: reasons for difficulties in making a diagnosis in young males. Am J Med Genet 2000; 92:229.</a></li><li><a class="nounderline abstract_t">Butler MG, Brunschwig A, Miller LK, Hagerman RJ. Standards for selected anthropometric measurements in males with the fragile X syndrome. Pediatrics 1992; 89:1059.</a></li><li><a class="nounderline abstract_t">Cantú JM, Scaglia HE, Medina M, et al. Inherited congenital normofunctional testicular hyperplasia and mental deficiency. Hum Genet 1976; 33:23.</a></li><li><a class="nounderline abstract_t">Cantú JM, Scaglia HE, González-Diddi M, et al. Inherited congenital normofunctional testicular hyperplasia and mental deficiency. A corroborative study. Hum Genet 1978; 41:331.</a></li><li><a class="nounderline abstract_t">Laxova R. Fragile X syndrome. Adv Pediatr 1994; 41:305.</a></li><li><a class="nounderline abstract_t">Hagerman RJ, Van Housen K, Smith AC, McGavran L. Consideration of connective tissue dysfunction in the fragile X syndrome. Am J Med Genet 1984; 17:111.</a></li><li><a class="nounderline abstract_t">Davids JR, Hagerman RJ, Eilert RE. Orthopaedic aspects of fragile-X syndrome. J Bone Joint Surg Am 1990; 72:889.</a></li><li><a class="nounderline abstract_t">Lachiewicz AM, Dawson DV. Do young boys with fragile X syndrome have macroorchidism? Pediatrics 1994; 93:992.</a></li><li><a class="nounderline abstract_t">Reiss AL, Aylward E, Freund LS, et al. Neuroanatomy of fragile X syndrome: the posterior fossa. Ann Neurol 1991; 29:26.</a></li><li><a class="nounderline abstract_t">Hessl D, Rivera SM, Reiss AL. The neuroanatomy and neuroendocrinology of fragile X syndrome. Ment Retard Dev Disabil Res Rev 2004; 10:17.</a></li><li><a class="nounderline abstract_t">Reiss AL, Abrams MT, Greenlaw R, et al. Neurodevelopmental effects of the FMR-1 full mutation in humans. Nat Med 1995; 1:159.</a></li><li><a class="nounderline abstract_t">Kau AS, Meyer WA, Kaufmann WE. Early development in males with Fragile X syndrome: a review of the literature. Microsc Res Tech 2002; 57:174.</a></li><li><a class="nounderline abstract_t">Reiss AL, Hall SS. Fragile X syndrome: assessment and treatment implications. Child Adolesc Psychiatr Clin N Am 2007; 16:663.</a></li><li><a class="nounderline abstract_t">Borghgraef M, Swillen A, Van den Berghe H, Fryns JP. Fragile X boys: evolution of the mental age in childhood. Preliminary data on 10 prepubertal boys. Genet Couns 1995; 6:97.</a></li><li><a class="nounderline abstract_t">Fisch GS, Simensen R, Tarleton J, et al. Longitudinal study of cognitive abilities and adaptive behavior levels in fragile X males: a prospective multicenter analysis. Am J Med Genet 1996; 64:356.</a></li><li><a class="nounderline abstract_t">Klaiman C, Quintin EM, Jo B, et al. Longitudinal profiles of adaptive behavior in fragile X syndrome. Pediatrics 2014; 134:315.</a></li><li><a class="nounderline abstract_t">Skinner M, Hooper S, Hatton DD, et al. Mapping nonverbal IQ in young boys with fragile X syndrome. Am J Med Genet A 2005; 132A:25.</a></li><li><a class="nounderline abstract_t">Roberts JE, Mirrett P, Burchinal M. Receptive and expressive communication development of young males with fragile X syndrome. Am J Ment Retard 2001; 106:216.</a></li><li class="breakAll">Tsai AC, Pickler L, Tartaglia N, Hagerman R. Chromosomal disorders and fragile X syndrome. In: Developmental-behavioral pediatrics, 4th ed, Carey WB, Crocker AC, Coleman WL, et al (Eds), Saunders Elsevier, Philadelphia 2009. p.224.</li><li><a class="nounderline abstract_t">Sudhalter V, Belser RC. Conversational characteristics of children with fragile X syndrome: tangential language. Am J Ment Retard 2001; 106:389.</a></li><li><a class="nounderline abstract_t">Borghgraef M, Fryns JP, Dielkens A, et al. Fragile (X) syndrome: a study of the psychological profile in 23 prepubertal patients. Clin Genet 1987; 32:179.</a></li><li><a class="nounderline abstract_t">Kemper MB, Hagerman RJ, Altshul-Stark D. Cognitive profiles of boys with the fragile X syndrome. Am J Med Genet 1988; 30:191.</a></li><li><a class="nounderline abstract_t">Freund LS, Reiss AL. Cognitive profiles associated with the fra(X) syndrome in males and females. Am J Med Genet 1991; 38:542.</a></li><li><a class="nounderline abstract_t">Schmitt LM, Shaffer RC, Hessl D, Erickson C. Executive Function in Fragile X Syndrome: A Systematic Review. Brain Sci 2019; 9.</a></li><li><a class="nounderline abstract_t">Kau AS, Reider EE, Payne L, et al. Early behavior signs of psychiatric phenotypes in fragile X syndrome. Am J Ment Retard 2000; 105:286.</a></li><li><a class="nounderline abstract_t">Budimirovic DB, Bukelis I, Cox C, et al. Autism spectrum disorder in Fragile X syndrome: differential contribution of adaptive socialization and social withdrawal. Am J Med Genet A 2006; 140A:1814.</a></li><li><a class="nounderline abstract_t">Baumgardner TL, Reiss AL, Freund LS, Abrams MT. Specification of the neurobehavioral phenotype in males with fragile X syndrome. Pediatrics 1995; 95:744.</a></li><li><a class="nounderline abstract_t">Reiss AL, Freund L. Behavioral phenotype of fragile X syndrome: DSM-III-R autistic behavior in male children. Am J Med Genet 1992; 43:35.</a></li><li><a class="nounderline abstract_t">Garber KB, Visootsak J, Warren ST. Fragile X syndrome. Eur J Hum Genet 2008; 16:666.</a></li><li><a class="nounderline abstract_t">Tsiouris JA, Brown WT. Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy. CNS Drugs 2004; 18:687.</a></li><li><a class="nounderline abstract_t">Berry-Kravis E, Potanos K. Psychopharmacology in fragile X syndrome--present and future. Ment Retard Dev Disabil Res Rev 2004; 10:42.</a></li><li><a class="nounderline abstract_t">Kaufmann WE, Cortell R, Kau AS, et al. Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors. Am J Med Genet A 2004; 129A:225.</a></li><li class="breakAll">FXCRC Consensus Statement. https://fragilex.org/wp-content/uploads/2012/08/Autism-Spectrum-Disorder-in-Fragile-X-Syndrome-2014-Nov.pdf.</li><li><a class="nounderline abstract_t">Bailey DB Jr, Mesibov GB, Hatton DD, et al. Autistic behavior in young boys with fragile X syndrome. J Autism Dev Disord 1998; 28:499.</a></li><li><a class="nounderline abstract_t">Philofsky A, Hepburn SL, Hayes A, et al. Linguistic and cognitive functioning and autism symptoms in young children with fragile X syndrome. Am J Ment Retard 2004; 109:208.</a></li><li><a class="nounderline abstract_t">Kaufmann WE, Kidd SA, Andrews HF, et al. Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment. Pediatrics 2017; 139:S194.</a></li><li><a class="nounderline abstract_t">Abbeduto L, Thurman AJ, McDuffie A, et al. ASD Comorbidity in Fragile X Syndrome: Symptom Profile and Predictors of Symptom Severity in Adolescent and Young Adult Males. J Autism Dev Disord 2019; 49:960.</a></li><li><a class="nounderline abstract_t">Hagerman PJ, Stafstrom CE. Origins of epilepsy in fragile X syndrome. Epilepsy Curr 2009; 9:108.</a></li><li><a class="nounderline abstract_t">Berry-Kravis E. Epilepsy in fragile X syndrome. Dev Med Child Neurol 2002; 44:724.</a></li><li><a class="nounderline abstract_t">Berry-Kravis E, Filipink RA, Frye RE, et al. Seizures in Fragile X Syndrome: Associations and Longitudinal Analysis of a Large Clinic-Based Cohort. Front Pediatr 2021; 9:736255.</a></li><li><a class="nounderline abstract_t">Fryns JP, Haspeslagh M, Dereymaeker AM, et al. A peculiar subphenotype in the fra(X) syndrome: extreme obesity-short stature-stubby hands and feet-diffuse hyperpigmentation. Further evidence of disturbed hypothalamic function in the fra(X) syndrome? Clin Genet 1987; 32:388.</a></li><li><a class="nounderline abstract_t">de Vries BB, Fryns JP, Butler MG, et al. Clinical and molecular studies in fragile X patients with a Prader-Willi-like phenotype. J Med Genet 1993; 30:761.</a></li><li><a class="nounderline abstract_t">Schrander-Stumpel C, Gerver WJ, Meyer H, et al. Prader-Willi-like phenotype in fragile X syndrome. Clin Genet 1994; 45:175.</a></li><li><a class="nounderline abstract_t">Nowicki ST, Tassone F, Ono MY, et al. The Prader-Willi phenotype of fragile X syndrome. J Dev Behav Pediatr 2007; 28:133.</a></li><li><a class="nounderline abstract_t">Hagerman RJ, Jackson C, Amiri K, et al. Girls with fragile X syndrome: physical and neurocognitive status and outcome. Pediatrics 1992; 89:395.</a></li><li><a class="nounderline abstract_t">Franke P, Leboyer M, Hardt J, et al. Neuropsychological profiles of FMR-1 premutation and full-mutation carrier females. Psychiatry Res 1999; 87:223.</a></li><li><a class="nounderline abstract_t">Bennetto L, Pennington BF, Porter D, et al. Profile of cognitive functioning in women with the fragile X mutation. Neuropsychology 2001; 15:290.</a></li><li><a class="nounderline abstract_t">de Vries BB, Wiegers AM, Smits AP, et al. Mental status of females with an FMR1 gene full mutation. Am J Hum Genet 1996; 58:1025.</a></li><li><a class="nounderline abstract_t">Willemsen R, Olmer R, De Diego Otero Y, Oostra BA. Twin sisters, monozygotic with the fragile X mutation, but with a different phenotype. J Med Genet 2000; 37:603.</a></li><li><a class="nounderline abstract_t">Freund LS, Reiss AL, Abrams MT. Psychiatric disorders associated with fragile X in the young female. Pediatrics 1993; 91:321.</a></li><li><a class="nounderline abstract_t">Hagerman RJ, Hills J, Scharfenaker S, Lewis H. Fragile X syndrome and selective mutism. Am J Med Genet 1999; 83:313.</a></li><li><a class="nounderline abstract_t">Keysor CS, Mazzocco MM. A developmental approach to understanding Fragile X syndrome in females. Microsc Res Tech 2002; 57:179.</a></li><li><a class="nounderline abstract_t">Cronister A, Hagerman RJ, Wittenberger M, Amiri K. Mental impairment in cytogenetically positive fragile X females. Am J Med Genet 1991; 38:503.</a></li><li><a class="nounderline abstract_t">Reiss AL, Hagerman RJ, Vinogradov S, et al. Psychiatric disability in female carriers of the fragile X chromosome. Arch Gen Psychiatry 1988; 45:25.</a></li><li><a class="nounderline abstract_t">Mazzocco MM, Kates WR, Baumgardner TL, et al. Autistic behaviors among girls with fragile X syndrome. J Autism Dev Disord 1997; 27:415.</a></li><li><a class="nounderline abstract_t">Wheeler A, Raspa M, Hagerman R, et al. Implications of the FMR1 Premutation for Children, Adolescents, Adults, and Their Families. Pediatrics 2017; 139:S172.</a></li><li><a class="nounderline abstract_t">Tassone F, Hagerman RJ, Taylor AK, et al. Clinical involvement and protein expression in individuals with the FMR1 premutation. Am J Med Genet 2000; 91:144.</a></li><li><a class="nounderline abstract_t">Aziz M, Stathopulu E, Callias M, et al. Clinical features of boys with fragile X premutations and intermediate alleles. Am J Med Genet B Neuropsychiatr Genet 2003; 121B:119.</a></li><li><a class="nounderline abstract_t">Farzin F, Perry H, Hessl D, et al. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. J Dev Behav Pediatr 2006; 27:S137.</a></li><li><a class="nounderline abstract_t">Kraan CM, Hocking DR, Bradshaw JL, et al. Neurobehavioural evidence for the involvement of the FMR1 gene in female carriers of fragile X syndrome. Neurosci Biobehav Rev 2013; 37:522.</a></li><li><a class="nounderline abstract_t">Lozano R, Rosero CA, Hagerman RJ. Fragile X spectrum disorders. Intractable Rare Dis Res 2014; 3:134.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Delayed diagnosis of fragile X syndrome--United States, 1990-1999. MMWR Morb Mortal Wkly Rep 2002; 51:740.</a></li><li><a class="nounderline abstract_t">Bailey DB Jr, Raspa M, Bishop E, Holiday D. No change in the age of diagnosis for fragile x syndrome: findings from a national parent survey. Pediatrics 2009; 124:527.</a></li><li><a class="nounderline abstract_t">Hersh JH, Saul RA, Committee on Genetics. Health supervision for children with fragile X syndrome. Pediatrics 2011; 127:994.</a></li><li><a class="nounderline abstract_t">Rauch A, Hoyer J, Guth S, et al. Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardation. Am J Med Genet A 2006; 140:2063.</a></li><li><a class="nounderline abstract_t">Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing. Genet Med 2005; 7:584.</a></li><li class="breakAll">Wilson GN, Cooley WC. The fragile X syndrome. In: Preventive management of children with congenital anomalies and syndromes, Cambridge University Press, Cambridge, United Kingdom 2000. p.175.</li><li><a class="nounderline abstract_t">Wiesner GL, Cassidy SB, Grimes SJ, et al. Clinical consult: developmental delay/fragile X syndrome. Prim Care 2004; 31:621.</a></li></ol></div><div id="topicVersionRevision">Topic 2924 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8826475" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prevalence of fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1710175" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22001764" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Advances in understanding fragile X syndrome and related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22001764" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Advances in understanding fragile X syndrome and related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19117905" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Advances in the treatment of fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8490650" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A point mutation in the FMR-1 gene associated with fragile X mental retardation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18412117" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Mosaic FMR1 deletion causes fragile X syndrome and can lead to molecular misdiagnosis: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12529854" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25210937" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Fragile X full mutation expansions are inhibited by one or more AGG interruptions in premutation carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25120560" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The role of AGG interruptions in fragile X repeat expansions: a twenty-year perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18074381" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Fragile X full mutation alleles composed of few alleles: implications for CGG repeat expansion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28960184" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24700618" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Epidemiology of fragile X syndrome: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9326332" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Screening and diagnosis for the fragile X syndrome among the mentally retarded: an epidemiological and psychological survey. Collaborative Fragile X Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7485149" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevalence of carriers of premutation-size alleles of the FMRI gene--and implications for the population genetics of the fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16047089" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Genetic counseling for fragile x syndrome: updated recommendations of the national society of genetic counselors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8213810" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Evidence that methylation of the FMR-I locus is responsible for variable phenotypic expression of the fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8844089" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Molecular-clinical correlations in males with an expanded FMR1 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8844079" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A controlled study of longitudinal IQ changes in females and males with fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15965543" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Fragile X syndrome: an update and review for the primary pediatrician.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32505083" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Disentangling autism spectrum and attention-deficit/hyperactivity symptoms over development in fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17022076" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : ADHD symptoms in children with FXS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6499265" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The fragile X syndrome. A study of 83 families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10842286" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Physical characteristics of young boys with fragile X syndrome: reasons for difficulties in making a diagnosis in young males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1594348" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Standards for selected anthropometric measurements in males with the fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/939556" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Inherited congenital normofunctional testicular hyperplasia and mental deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/649159" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Inherited congenital normofunctional testicular hyperplasia and mental deficiency. A corroborative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7992687" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6711590" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Consideration of connective tissue dysfunction in the fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2195034" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Orthopaedic aspects of fragile-X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8190590" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Do young boys with fragile X syndrome have macroorchidism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1996876" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Neuroanatomy of fragile X syndrome: the posterior fossa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14994284" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The neuroanatomy and neuroendocrinology of fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7585014" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Neurodevelopmental effects of the FMR-1 full mutation in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12112454" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Early development in males with Fragile X syndrome: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17562585" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Fragile X syndrome: assessment and treatment implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7546457" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Fragile X boys: evolution of the mental age in childhood. Preliminary data on 10 prepubertal boys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8844080" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Longitudinal study of cognitive abilities and adaptive behavior levels in fragile X males: a prospective multicenter analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25070318" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Longitudinal profiles of adaptive behavior in fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15551333" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mapping nonverbal IQ in young boys with fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11389664" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Receptive and expressive communication development of young males with fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11389664" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Receptive and expressive communication development of young males with fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11531459" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Conversational characteristics of children with fragile X syndrome: tangential language.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3621665" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Fragile (X) syndrome: a study of the psychological profile in 23 prepubertal patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3177444" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cognitive profiles of boys with the fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2063895" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cognitive profiles associated with the fra(X) syndrome in males and females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30654486" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Executive Function in Fragile X Syndrome: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10934570" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Early behavior signs of psychiatric phenotypes in fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16906564" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Autism spectrum disorder in Fragile X syndrome: differential contribution of adaptive socialization and social withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7724315" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Specification of the neurobehavioral phenotype in males with fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1605210" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Behavioral phenotype of fragile X syndrome: DSM-III-R autistic behavior in male children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18398441" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15330685" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14994287" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Psychopharmacology in fragile X syndrome--present and future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15326621" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15326621" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9932236" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Autistic behavior in young boys with fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15072521" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Linguistic and cognitive functioning and autism symptoms in young children with fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28814540" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30382442" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : ASD Comorbidity in Fragile X Syndrome: Symptom Profile and Predictors of Symptom Severity in Adolescent and Young Adult Males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19693328" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Origins of epilepsy in fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12418611" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Epilepsy in fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35036394" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Seizures in Fragile X Syndrome: Associations and Longitudinal Analysis of a Large Clinic-Based Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3436088" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A peculiar subphenotype in the fra(X) syndrome: extreme obesity-short stature-stubby hands and feet-diffuse hyperpigmentation. Further evidence of disturbed hypothalamic function in the fra(X) syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8411072" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Clinical and molecular studies in fragile X patients with a Prader-Willi-like phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8062434" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prader-Willi-like phenotype in fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17435464" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The Prader-Willi phenotype of fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1741210" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Girls with fragile X syndrome: physical and neurocognitive status and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10579555" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Neuropsychological profiles of FMR-1 premutation and full-mutation carrier females</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11324870" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Profile of cognitive functioning in women with the fragile X mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8651263" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Mental status of females with an FMR1 gene full mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10922388" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Twin sisters, monozygotic with the fragile X mutation, but with a different phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8380924" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Psychiatric disorders associated with fragile X in the young female.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10208168" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Fragile X syndrome and selective mutism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12112455" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A developmental approach to understanding Fragile X syndrome in females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2018094" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Mental impairment in cytogenetically positive fragile X females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3337608" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Psychiatric disability in female carriers of the fragile X chromosome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9261667" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Autistic behaviors among girls with fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28814538" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Implications of the FMR1 Premutation for Children, Adolescents, Adults, and Their Families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10748416" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Clinical involvement and protein expression in individuals with the FMR1 premutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12898586" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Clinical features of boys with fragile X premutations and intermediate alleles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16685180" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23352653" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Neurobehavioural evidence for the involvement of the FMR1 gene in female carriers of fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25606363" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Fragile X spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12201607" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Delayed diagnosis of fragile X syndrome--United States, 1990-1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19581269" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : No change in the age of diagnosis for fragile x syndrome: findings from a national parent survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21518720" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Health supervision for children with fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16917849" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16247297" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Fragile X syndrome: diagnostic and carrier testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16247297" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Fragile X syndrome: diagnostic and carrier testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15331251" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Clinical consult: developmental delay/fragile X syndrome.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
